neuroClues

What we do: neuroClues is a MedTech company specializing in early diagnosis of neurological disorders such as Parkinson's disease, Alzheimer's disease, and multiple sclerosis. Using advanced AI-driven eye-tracking technology, neuroClues provides clinicians with non-invasive biomarkers that detect these conditions years before visible symptoms appear. Their portable device analyzes eye movements rapidly and accurately, enhancing neurologic care and supporting both clinical practice and research in pharmaceutical, biotech, and healthcare sectors.

Where we are located: The company is headquartered at Centre Monnet, Av. Jean Monnet 1, 1348 Ottignies-Louvain-la-Neuve, Belgium, with additional offices in Paris, France, and New York, USA.

Short history: Founded by experienced MedTech entrepreneurs and physicians, neuroClues has developed its technology based on over 60 years of eye movement research. The company has secured CE marking as a Class IIa medical device, enabling clinical use across Europe. Since its establishment about three and a half years ago, neuroClues has focused on transforming neurological diagnostics with innovative, pragmatic solutions.

Organization & culture: neuroClues fosters a culture of innovation, collaboration, and excellence. The team comprises researchers, doctors, and engineers working in a flexible environment that values teamwork and entrepreneurship. The company is committed to advancing neurological care and improving patient quality of life globally.

Recent developments: neuroClues recently obtained CE certification for its eye-tracking technology, now available for clinical use in Europe. The device is designed to complement existing diagnostic methods by providing rapid, objective biomarkers. The company aims to support 10 million patients by 2030 and is expanding its reach in European and American markets.